Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™

Osteoporosis International

Volumn 21, Issue 10, 2010, Pages 1769-1780

  Tosteson, A N A ^e   Do, T P ^a   Wade, S W ^b   Anthony, M S ^c   Downs, R W ^d  

^a AMGEN INC   (United States)

^b Wade Outcomes Research and Consulting   (United States)

^c AMGEN INC   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

Discontinuation; Medication; Persistence; Postmenopausal osteoporosis; Switching

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; CALCITONIN; CALCIUM; CALCIUM PLUS RISEDRONIC ACID; ESTROGEN; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

AGED; BONE DENSITY CONSERVATION AGENTS; DRUG SUBSTITUTION; DRUG UTILIZATION; EDUCATIONAL STATUS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 77956403912     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1133-5     Document Type: Article

References (18)

1. SW Fletcher GA Colditz 2002 Failure of estrogen plus progestin therapy for prevention JAMA 288 366 368 10.1001/jama.288.3.366 12117403
2. JE Rossouw 2002 Effect of postmenopausal hormone therapy on cardiovascular risk J Hypertens Suppl 20 S62 S65 1:CAS:528:DC%2BD38Xks12mtro%3D 12183856
3. P Kothawala E Badamgarav S Ryu RM Miller RJ Halbert 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493 1501 10.4065/82.12.1493 18053457
4. JA Cramer DT Gold SL Silverman EM Lewiecki 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023 1031 1:CAS:528:DC%2BD2sXntVOlsrY%3D 10.1007/s00198-006-0322-8 17308956
5. TW Downey SH Foltz SJ Boccuzzi MA Omar KH Kahler 2006 Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting South Med J 99 570 575 10.1097/01.smj.0000221637.90495.66 16800411
6. M Rossini G Bianchi MO Di S Giannini S Minisola L Sinigaglia S Adami 2006 Determinants of adherence to osteoporosis treatment in clinical practice Osteoporos Int 17 914 921 1:STN:280:DC%2BD283osVKltg%3D%3D 10.1007/s00198-006- 0073-6 16538553
7. J Kayser B Ettinger A Pressman 2001 Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen Menopause 8 328 332 1:STN:280:DC%2BD3MvosF2quw%3D%3D 10.1097/00042192-200109000-00006 11528358
8. E Barrett-Connor K Ensrud AN Tosteson SF Varon M Anthony N Daizadeh S Wade 2009 Design of the POSSIBLE US™ Study: postmenopausal women's compliance and persistence with osteoporosis medications Osteoporos Int 20 463 472 1:STN:280:DC%2BD1M7jtlSnsA%3D%3D 10.1007/s00198-008-0674-3 18607669
9. MJ Atkinson A Sinha SL Hass SS Colman RN Kumar M Brod CR Rowland 2004 Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease Health Qual Life Outcomes 2 12 10.1186/1477-7525-2-12 14987333
10. R Brooks 1996 EuroQol: the current state of play Health Policy 37 53 72 1:STN:280:DyaK283otFKhsg%3D%3D 10.1016/0168-8510(96)00822-6 10158943
11. AG Randell N Bhalerao TV Nguyen PN Sambrook JA Eisman SL Silverman 1998 Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis Assessment Questionnaire J Rheumatol 25 1171 1179 1:STN:280:DyaK1c3ptlynsQ%3D%3D 9632082
12. AM Gallagher S Rietbrock M Olson TP van Staa 2008 Fracture outcomes related to persistence and compliance with oral bisphosphonates J Bone Miner Res 23 1569 1575 10.1359/jbmr.080510 18505366
13. FE Cotte F Mercier PG De 2008 Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis Clin Ther 30 2410 2422 10.1016/j.clinthera.2008.12.019 19167600
14. ES Siris PL Selby KG Saag F Borgstrom RM Herings SL Silverman 2009 Impact of osteoporosis treatment adherence on fracture rates in North America and Europe Am J Med 122 S3 S13 10.1016/j.amjmed.2008.12.002 19187810
15. R Burge B wson-Hughes DH Solomon JB Wong A King A Tosteson 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465 475 10.1359/jbmr.061113 17144789
16. AN Tosteson MR Grove CS Hammond MM Moncur GT Ray GM Hebert AR Pressman B Ettinger 2003 Early discontinuation of treatment for osteoporosis Am J Med 115 209 216 10.1016/S0002-9343(03)00362-0 12947959
17. CA McHorney JT Schousboe RR Cline TW Weiss 2007 The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates Curr Med Res Opin 23 3137 3152 1:CAS:528: DC%2BD1cXhslOktr0%3D 10.1185/030079907X242890 17988435
18. H Ideguchi S Ohno K Takase A Ueda Y Ishigatsubo 2008 Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital Osteoporos Int 19 1777 1783 1:CAS:528:DC%2BD1cXht12kur7I 10.1007/s00198-008-0618-y 18458987